Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Chemotherapy in Recurrent/Metastatic NPC
NCT06241599Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nasopharyngeal carcinoma (NPC) comparing AK104 + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoint: Progression-Free Survival at 24 months. Started Feb 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06241599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241599.